Scarica l'app Stockscreener
0.4505
2.68%
-0.0124
Precedente Chiudi:
$0.4629
Aprire:
$0.4762
Volume 24 ore:
1.53M
Relative Volume:
0.71
Capitalizzazione di mercato:
$44.17M
Reddito:
$190.00K
Utile/perdita netta:
$-70.03M
Rapporto P/E:
-0.6135
EPS:
-0.7343
Flusso di cassa netto:
$-59.30M
1 W Prestazione:
-5.24%
1M Prestazione:
-13.28%
6M Prestazione:
-35.93%
1 anno Prestazione:
-91.29%
Intervallo 1D:
$0.4501
$0.4883
Intervallo di 1 settimana:
$0.44
$0.4972
Portata 52W:
$0.395
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.4505 | 44.17M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
aTyr Pharma Ord Shs (LIFE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Inc (ATYR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
aTyr Pharma Inc (ATYR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
aTyr Pharma Inc (ATYR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
aTyr Pharma Inc (ATYR) Valuation: PE, PB & Fair Value Analysis - TradingKey
aTyr Pharma Ord Shs (LIFE) Institutional Confidence - TradingKey
aTyr Pharma Inc (ATYR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
aTyr Pharma Inc (ATYR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
aTyr Pharma Inc (ATYR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Inc (ATYR) Institutional Confidence - TradingKey
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC Significantly Reduces Holdings in aTyr Pharma Inc - GuruFocus
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
aTyr Pharma Company Profile & Introduction - Moomoo
aTyr Pharma Granted Nasdaq Extension to Regain Compliance - The Globe and Mail
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide - simplywall.st
aTyr Pharma Received Notice of Noncompliance - TradingView
aTyr Pharma (NASDAQ: ATYR) wins second Nasdaq deadline to fix sub-$1 share price - Stock Titan
aTyr Pharma (ATYR) Faces Steep Decline as Shares Test Key Support ZoneJelly Roll Trade - lwvtexas.org
FMR LLC discloses 5.94M-share stake in ATYR (NASDAQ: ATYR) Amendment No.14 - Stock Titan
aTyr Pharma Inc stock (US53227K1025): shares ease after efzofitimod Phase III plan and major holder - AD HOC NEWS
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis - TipRanks
aTyr Pharma (ATYR) Price Target Decreased by 37.13% to 6.48 - MSN
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data - TipRanks
aTyr Pharma (ATYR) refocuses efzofitimod after EFZO-FIT miss with new Phase 3 sarcoidosis trial - Stock Titan
aTyr Pharma Inc stock (US53227K1025): Insider buying and price gains draw focus - AD HOC NEWS
aTYR Pharma director Paul Schimmel buys $49,630 in common stock By Investing.com - Investing.com Australia
aTYR Pharma director Paul Schimmel buys $49,630 in common stock - Investing.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Director at aTyr Pharma (NASDAQ: ATYR) adds 100K shares - Stock Titan
aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug - Investing.com Nigeria
aTyr Pharma (ATYR) Slips 1.22%, Approaching Key Support at $0.46Total Put Call - newsline.com
aTyr Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Some Relief Amid Pipeline DevelopmentBasic EPS Analysis - newsline.com
Why Is aTyr Stock Falling Today? - MSN
aTyr Pharma (ATYR) Stock Forecast & Analyst Ratings - Moomoo
aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus - AD HOC NEWS
ATyr Pharma revamps efzofitimod path with new phase III sarcoidosis trial - MSN
Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5 - Moomoo
ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50 - GuruFocus
ATyr Pharma Raised to Buy From Hold by Freedom Broker - Moomoo
ATyr Pharma Price Target Raised to $3.50/Share From $1.00 by Freedom Broker - Moomoo
aTyr Pharma upgraded to Buy from Hold at Freedom Broker - TipRanks
Freedom Broker upgrades ATYR Pharma (ATYR) - MSN
Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma stock (US0021202025): fresh quarterly loss keeps biotech in focus - AD HOC NEWS
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86 - TradingView
aTyr Pharma Inc stock (US53227K1025): biotech under pressure as short interest jumps and earnings su - AD HOC NEWS
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
[10-Q] aTYR PHARMA INC Quarterly Earnings Report - Stock Titan
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shukla Sanjay | President and CEO |
Feb 04 '26 |
Sale |
0.98 |
3,745 |
3,655 |
153,553 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):